Page 1496 - Hematology_ Basic Principles and Practice ( PDFDrive )

1329.e2 Part VII Hematologic Malignancies

evaluation for pleural effusion in patients receiving hemodialysis. Case emphasis on preconditioning regimen: a nationwide retrospective study.
Rep Nephrol Urol 4:95, 2014. Blood 120:1734, 2012.
47. Cannon JS, Nicholas J, Orenstein JM, et al: Heterogeneity of viral IL-6 68. Epeldegui M, Vendrame E, Martínez-Maza O: HIV-associated immune
expression in HHV-8-associated diseases. J Infect Dis 180:824, 1999. dysfunction and viral infection: role in the pathogenesis of AIDS-
48. Du MQ, Liu H, Diss TC, et al: Kaposi sarcoma-associated herpesvi- related lymphoma. Immunol Res 48:72, 2010.
rus infects monotypic (IgM lambda) but polyclonal naive B cells in 69. Shen L, Siliciano RF: Viral reservoirs, residual viremia, and the poten-
Castleman disease and associated lymphoproliferative disorders. Blood tial of highly active antiretroviral therapy to eradicate HIV infection.
97:2130, 2001. J Allergy Clin Immunol 122:22, 2008.
49. Halfdanarson TR, Markovic SN, Kalokhe U, et al: A non-chemotherapy 70. Gaidano G, Pasqualucci L, Capello D, et al: Aberrant somatic
treatment of a primary effusion lymphoma: durable remission after hypermutation in multiple subtypes of AIDS-associated non-Hodgkin
intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. lymphoma. Blood 102:1833, 2003.
Ann Oncol 17:1849, 2006. 71. Epeldegui M, Thapa DR, De La Cruz J, et al: CD40 ligand (CD154)
50. Bower M, Newsom-Davis T, Naresh K, et al: Clinical Features and incorporated into HIV virions induces activation-induced cytidine
Outcome in HIV-Associated Multicentric Castleman’s Disease. J Clin deaminase (AID) expression in human B lymphocytes. PLoS ONE
Oncol 29:2481, 2011. 5:e11448, 2010.
51. Casper C: The aetiology and management of Castleman disease at 50 72. Dean M, Jacobson LP, McFarlane G, et al: Reduced risk of AIDS
years: translating pathophysiology to patient care. Br J Haematol 129:3, lymphoma in individuals heterozygous for the CCR5-Δ32 mutation.
2005. Cancer Res 59:3561, 1999.
52. van Rhee F, Wong RS, Munshi N, et al: Siltuximab for multicentric 73. Goedert JJ: The epidemiology of acquired immunodeficiency syndrome
Castleman’s disease: a randomised, double-blind, placebo-controlled malignancies. Semin Oncol 27:390, 2000.
trial. Lancet Oncol 15:966, 2014. 74. Levine AM: HIV-associated lymphoma. Blood 115:2986, 2010.
53. Uldrick TS, Polizzotto MN, Aleman K, et al: High-dose zidovudine 75. Bohlius J, Schmidlin K, Costagliola D, et al: Incidence and risk factors
plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicen- of HIV-related non-Hodgkin’s lymphoma in the era of combination
tric Castleman disease: a pilot study of virus-activated cytotoxic therapy. antiretroviral therapy: a European multicohort study. Antivir Ther
Blood 117:6977, 2011. 14:1065, 2009.
54. Uldrick TS, Polizzotto MN, Aleman K, et al: Rituximab plus liposomal 76. Bruyand M, Ryom L, Shepherd L, et al: Cancer risk and use of protease
doxorubicin in HIV-infected patients with KSHV-associated multicen- inhibitor or nonnucleoside reverse transcriptase inhibitor-based combi-
tric Castleman disease. Blood 124:3544, 2014. nation antiretroviral therapy: the D: A: D study. J Acquir Immune Defic
55. Yamano Y, Cohen CJ, Takenouchi N, et al: Increased expression of Syndr 68:568, 2015.
human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human 77. Bonnet F, Lewden C, May T, et al: Malignancy-related causes of death
+
+
histocompatibility leukocyte antigen A*201 complexes on CD4 CD25 in human immunodeficiency virus-infected patients in the era of highly
T cells detected by peptide-specific, major histocompatibility complex- active antiretroviral therapy. Cancer 101:317, 2004.
restricted antibodies in patients with HTLV-I-associated neurologic 78. Engels EA, Pfeiffer RM, Landgren O, et al: Immunologic and virologic
disease. J Exp Med 199:1367, 2004. predictors of AIDS-related non-Hodgkin lymphoma in the highly
56. Bellon M, Baydoun HH, Yao Y, et al: HTLV-I Tax-dependent and active antiretroviral therapy era. J Acquir Immune Defic Syndr 54:78,
-independent events associated with immortalization of human primary 2010.
T lymphocytes. Blood 115:2441, 2010. 79. Biggar RJ, Jaffe ES, Goedert JJ, et al: Hodgkin lymphoma and immu-
57. Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV- nodeficiency in persons with HIV/AIDS. Blood 108:3786, 2006.
1) infectivity and cellular transformation. Nat Rev Cancer 7:270, 2007. 80. Gopal S, Martin KE, Richards KL, et al: Clinical presentation, treat-
58. Matsuoka M, Jeang KT: Human T-cell leukemia virus type 1 (HTLV-1) ment, and outcomes among 65 patients with HIV-associated lymphoma
and leukemic transformation: viral infectivity, Tax, HBZ and therapy. treated at the University of North Carolina, 2000-2010. AIDS Res Hum
Oncogene 30:1379, 2011. Retroviruses 28:798, 2012.
59. Sonoda S, Li HC, Tajima K: Ethnoepidemiology of HTLV-1 related 81. Guech-Ongey M, Simard EP, Anderson WF, et al: AIDS-related Burkitt
diseases: ethnic determinants of HTLV-1 susceptibility and its world- lymphoma in the United States: what do age and CD4 lymphocyte
wide dispersal. Cancer Sci 102:295, 2011. patterns tell us about etiology and/or biology? Blood 116:5600, 2010.
60. Koga Y, Iwanaga M, Soda M, et al: Trends in HTLV-1 prevalence and 82. Ambinder RF, Bhatia K, Martinez-Maza O, et al: Cancer biomarkers
incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan. J Med in HIV patients. Curr Opin HIV AIDS 5:531, 2010.
Virol 82:668, 2010. 83. Kaplan LD, Straus DJ, Testa MA, et al: Low-dose compared with
61. Bazarbachi A, Suarez F, Fields P, et al: How I treat adult T-cell leukemia/ standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma
lymphoma. Blood 118:1736, 2011. associated with human immunodeficiency virus infection. N Engl J Med
62. Tsukasaki K, Utsunomiya A, Fukuda H, et al: VCAP-AMP-VECP 336:1641, 1997.
compared with biweekly CHOP for adult T-cell leukemia-lymphoma: 84. Little RF, Pittaluga S, Grant N, et al: Highly effective treatment of
Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol acquired immunodeficiency syndrome-related lymphoma with dose-
25:5458, 2007. adjusted EPOCH: impact of antiretroviral therapy suspension and
63. Ishida T, Jo T, Takemoto S, et al: Dose-intensified chemotherapy alone tumor biology. Blood 101:4653, 2003.
or in combination with mogamulizumab in newly diagnosed aggressive 85. Ratner L, Lee J, Tang SH, et al: Chemotherapy for human immu-
adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J nodeficiency virus-associated non-Hodgkin’s lymphoma in combina-
Haematol 169:672, 2015. tion with highly active antiretroviral therapy. J Clin Oncol 19:2171,
64. Jiang L, Yuan CM, Hubacheck J, et al: Variable CD52 expression in 2001.
mature T cell and NK cell malignancies: implications for alemtuzumab 86. Mounier N, Spina M, Gabarre J, et al: AIDS-related non-Hodgkin
therapy. Br J Haematol 145:173, 2009. lymphoma: final analysis of 485 patients treated with risk-adapted
65. Morris J, Sharma K, O’Mahony D, et al: A phase II study of the efficacy intensive chemotherapy. Blood 107:3832, 2006.
and toxicity of alemtuzumab (Campath) for treatment of human T 87. Kaplan LD, Lee JY, Ambinder RF, et al: Rituximab does not improve
cell lymphotrophic virus-1 (HTLV-1)-associated adult T cell leukemia/ clinical outcome in a randomized phase 3 trial of CHOP with or
lymphoma (ATL) [abstract]. AIDS Res Hum Retroviruses 23:632, 2007. without rituximab in patients with HIV-associated non-Hodgkin lym-
66. Choi I, Tanosaki R, Uike N, et al: Long-term outcomes after hemato- phoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538,
poietic SCT for adult T-cell leukemia/lymphoma: results of prospective 2005.
trials. Bone Marrow Transplant 46:116, 2011. 88. Sparano JA, Lee JY, Kaplan LD, et al: Rituximab plus concurrent
67. Ishida T, Hishizawa M, Kato K, et al: Allogeneic hematopoietic stem infusional EPOCH chemotherapy is highly effective in HIV-associated
cell transplantation for adult T-cell leukemia-lymphoma with special B-cell non-Hodgkin lymphoma. Blood 115:3008, 2010.